OUR TEAM

Rami is a strategy advisor and corporate development expert with a certification in business and executive coaching. Rami specializes in helping pharmaceutical and biotech executives accelerate and amplify their results, identify and overcome obstacles to enhance their performance and contribute to the growth of their companies.

Rami is a seasoned biotech executive with nearly 30 years of experience in the pharmaceutical and biotechnology industries. He managed businesses with large P&Ls, has taken businesses through scale ups and fast growth. Led private and public companies and managed VC owned companies and has raised substantial and transformational capital.

Rami served as the Chief Executive Officer of ImStem Biotechnology, a clinical stage biotechnology company focused on stem cell research and development of treatments targeting autoimmune, degenerative, and rare orphan diseases. Prior to joining ImStem Rami was the President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for rare disease patients. At Saniona Rami raised transformational capital in a private placement, initiated three clinical trials and transformed the company from a research organization into a fully integrated company with newly established headquarters in the US. Prior to joining Saniona, Rami served as President of Sobi Inc., the North American affiliate of international rare disease company Sobi. At Sobi, Rami was a member of the Executive team of the company. He built and led the North American organization from infancy to a team of over 300 employees generating over half a billion USD in annual revenue. Rami’s experience in mergers and acquisitions resulted in the successful acquisitions of Gamifant, the first FDA approved treatment for primary hemophagocytic lymphohistiocytosis (pHLH), and Synagis, the only FDA approved prophylaxis for respiratory syncytial virus (RSV) at the time. Under his leadership, the Sobi team built and grew the Canadian affiliate, launched Gamifant and integrated the entire Synagis sales and medical organizations. Prior to joining Sobi, Rami held commercial leadership roles of increasing strategic importance for over 16 years at Merck Serono in several countries, including the U.S., Sweden, Switzerland and Israel and prior to that at Schering AG.

Rami earned his MBA from the Recanati Business School at Tel Aviv University in Israel, majoring in International Marketing, and has a BSc in Biology from Tel Aviv University.

Marc is a successful life sciences consultant, executive, and entrepreneur with more than 25 years of industry experience.  He provides leadership development, strategy and corporate development counsel to life science and biopharma companies to help executives and their organizations grow and succeed. Marc brings a unique combination of strategic insight and “been there” operational experience to business and leadership challenges. He is currently a Senior Fellow at the Tufts Center for the Study of Drug Development, where he researches and writes about the strategic issues driving the future of the life sciences industry.

Marc has held executive leadership positions in both public and private companies, including as CEO and co-founder. Most recently, he served as COO at Finch Therapeutics, where he directed key functions including finance, HR, facilities, IT, and program management. Prior to Finch, he was Head of Business Development at Guide Therapeutics, a leader in targeted delivery of gene therapies, which was acquired in 2021 for $440 million by Beam Therapeutics. Previously, he co-founded and served as CEO of multiple life sciences companies.  He served as CEO of NED Biosystems, a company developing a combination treatment for advanced solid tumor cancers.  Prior to that, he was co-founder and CEO of Akashi Therapeutics, a rare disease-focused company that he led from its inception through construction of a multi-product portfolio, generation of clinical data, and establishment of a $100 million strategic partnership with a mid-sized pharmaceutical company.  His prior experience encompasses leadership of key commercial, product development, business, and operations functions within biotechnology companies.  Previously, Marc held leadership roles at Dyax Corp (now Takeda) including Senior VP Manufacturing, Process, and Commercial Operations, and led development of the now-marketed product Kalbitor®.  Prior to joining Dyax, Marc held business development and program management leadership roles at Alkermes, where he initiated and led the development program for the now-marketed product Vivitrol®.  Earlier, Marc joined Genetics Institute (now Pfizer) to head business development within one of the firm’s business units.

Marc holds a Master’s Degree from Harvard University’s Kennedy School and BA in Biology from the University of Pennsylvania.  He is also a Chartered Financial Analyst (CFA) charterholder.